TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01905943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
Study: NCT01020409

Intervention type: PROCEDURE
Intervention: cardiac surgery with CPB use
Description: cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
Study: NCT03573206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)
Description: The device will be used to close all femoral venous access sites at the end of the case.
Study: NCT02034292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Study: NCT00717132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Behavior Modification
Description: Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
Study: NCT02034292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT02469987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYL-1402O
Description: Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US marketed Avastin(R)
Description: Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU marketed Avastin(R)
Description: Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
Study: NCT03370419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT03451513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pride Body Project
Description: PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media Advocacy
Description: We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
Study: NCT04119804

Intervention type: DIAGNOSTIC_TEST
Intervention: cellular neural networks-genetic algorithm
Description: Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: cellular neural networks-genetic algorithm
Description: Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
Study: NCT04599491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'
Description: Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'
Description: Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
Study: NCT04242628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook course
Description: The intervention consists of the attendance to a course on Facebook and Social Networking Sites use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Course
Description: The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
Study: NCT02651259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: 900 mg of RPT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: 900 mg of RPT
Study: NCT01422941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAVU Attune Device
Description: The CAVU Attune device is used with LAGB.
Study: NCT02651259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: 900 mg of INH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: 900 mg of INH
Study: NCT00107432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02651259

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: 25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: 25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Study: NCT00255983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem medoxomil
Description: 600 mg BID for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets BID for 5 days
Study: NCT00547989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard anaesthesia (bupivacaine)
Description: Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
Study: NCT01004653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (Split virion), Inactivated
Description: 100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
Study: NCT03915028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water
Study: NCT00524732

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular
Study: NCT00547989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: additional pvb (ropivacaine) and elastomeric disposable infusion pump
Description: Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
Study: NCT00524732

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis
Description: 0.5 mL, Intramuscular
Study: NCT05529667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054828, Paclitaxel
Description: phase 1\>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent.
Study: NCT02013674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hMSCs
Description: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hMSCs
Description: Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
Study: NCT02410980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.1%
Description: Assessment of the skin change
Study: NCT03620968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: 15 minutes day of brain training by an APP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: 15 minutes day of brain training by an APP
Study: NCT00351533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Description: Liquid fish oil 7.5cc enterally every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Description: Liquid fish oil 7.5cc enterally every 6 hours
Study: NCT00430820

Intervention type: PROCEDURE
Intervention: per intervention
Description: per intervention
Study: NCT00547989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: additional pvb (ropivacaine)
Description: Patients in group 1 will receive PVB with ropivacaine
Study: NCT00189436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Budesonide
Description: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (albuterol with or without oral steroid)
Description: Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT01666015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE (EX)
Description: This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games).
Study: NCT00662831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin/ Dalteparin Sodium
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Fragmin/ Dalteparin Sodium
Description: Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
Study: NCT01666015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group will be under standard care without any EX intervention.
Study: NCT04396327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: diphenhydramine, zolpidem and lorazepam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: diphenhydramine and lorazepam
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Study: NCT01479244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuVax™ vaccine
Description: E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leukine® (sargramostim, GM-CSF) and water for injection
Description: Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
Study: NCT02580032

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given.

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given.

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given.

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given.
Study: NCT03789656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, capsules, once daily by mouth
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Study: NCT00705380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents
Description: CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Study: NCT00705380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents
Description: CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
Study: NCT00705380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
Study: NCT01213511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting with the use of minimal extracorporeal circulation
Description: The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting under conventional extracorporeal circulation
Description: A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
Study: NCT03692195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WHOOP Strap 2.0
Description: The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Device
Description: The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
Study: NCT03477344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.